Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tranzyme Pharma has said that Philippa Charlton, MD of Tranzyme and her colleagues Bochicchio, JC Pezullo, Kosutic and Senagore, will present a poster entitled 'The Prokinetic Agent TZP-101 (a Ghrelin Agonist) Accelerates GI Recovery in Partial Colectomy Patients Independently of Total Opioid Use and Type of Surgery' at the upcoming 2010 Annual Scientific Meeting of the American Society of Colon and Rectal Surgeons (ASCRS; Minneapolis, May 15-19).
Subscribe to our email newsletter
Tranzyme said that the presentation examines predictors of gastrointestinal (GI) recovery in surgical patients who have undergone partial large bowel resection. The results indicated that although opioid use prolonged recovery slightly, it did not impact the ability of TZP-101 to accelerate recovery of bowel function, consistent with its opioid-independent mechanism of action.
Similarly, whereas the extent of opioid use varied by country (US, Romania, Lithuania, India), GI recovery in patients receiving TZP-101 was unaffected by the country in which it was tested further emphasizing that the efficacy of TZP-101 is not limited by the use of opioids for pain management.
Tranzyme is planning a Phase 3 program with TZP-101 for Patients with Postoperative Ileus (POI) with the primary efficacy endpoint of “GI2” – the time to recovery of GI motility as defined by the later of first bowel movement (BM) and first solid food intake.
POI is a multi-factorial, transient impairment of gastrointestinal (GI) motility following abdominal or other surgery. Symptoms include abdominal distention, pain, nausea and vomiting, and inability to pass stools and tolerate a solid diet. Delays in resuming a normal diet may lead to poor wound healing and increased risk of infection through a cascade of events.
The preceding Phase 2 study (which enrolled ~250 patients undergoing partial large bowel resection) demonstrated that TZP-101 reduced the time to GI2 by 23.3 hours over placebo (PBO), a difference both clinically and statistically significant (p<0.05).
The proportion of patients who had early recovery of GI motility (within 72 hours), another endpoint with clinical significance, was markedly increased by TZP-101 over placebo (65% versus 25%, respectively; p = 0.004). The most typical and clinically important adverse events for the post-surgical population, nausea and vomiting, were also noticeably decreased in the TZP-101 group as compared to placebo.
In the placebo group, nausea and vomiting were reported for 27% and 16% patients, respectively. In contrast, for the two most effective study doses, fewer than 5% of TZP-101 patients experienced nausea or vomiting, consistent with the strong GI prokinetic activity of TZP-101 and early recovery of GI motility (Senagore, et. al., Diseases of the Colon and Rectum, 2010).